<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01425398</url>
  </required_header>
  <id_info>
    <org_study_id>statins_inflammation_CVsurgery</org_study_id>
    <nct_id>NCT01425398</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Effect of Rosuvastatin on Inflammation in Patients Undergoing Isolated Cardiac Valve Surgery</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Effect of Rosuvastatin on Inflammation in Patients Undergoing Isolated Cardiac Valve Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High-dose statin therapy around the time of surgery, decreases inflammation in patients&#xD;
      undergoing cardiac valve surgery, and thereby improves clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improved Inflammatory Markers</measure>
    <time_frame>Within 5 days post-op and at 3 months</time_frame>
    <description>Significant (p&lt;0.05) improvement of measured inflammatory markers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Within 3 months</time_frame>
    <description>Significant (p&lt;0.05) reduction of mortality in rosuvastatin arm versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>Within 3 months</time_frame>
    <description>Significant (p&lt;0.05) reduction of stroke events in rosuvastatin arm versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>Within 3 months</time_frame>
    <description>Significant (p&lt;0.05) reduction of MI events in rosuvastatin arm versus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>3 months</time_frame>
    <description>Significant reduction (p&lt;0.05) of length of stay in rosuvastatin arm versus placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Valvular Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Rosuvastatin 40 mg/day</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Single or multiple valve repairs or replacements without coronary artery bypass&#xD;
             grafting&#xD;
&#xD;
          -  Bentall procedure, but no other aortic procedures&#xD;
&#xD;
          -  With or without accompanying MAZE procedure (surgical treatment for atrial&#xD;
             fibrillation)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 18 years old&#xD;
&#xD;
          -  Urgent or emergency surgery&#xD;
&#xD;
          -  Unable to provide consent&#xD;
&#xD;
          -  Presently on statin therapy or exposure to statins within a month of surgery&#xD;
&#xD;
          -  Chronic anti-inflammatory use, including steroids and NSAID's (nonsteroidal&#xD;
             anti-inflammatory drugs) (not to be used during the treatment period)&#xD;
&#xD;
          -  Known hypersensitivity to rosuvastatin&#xD;
&#xD;
          -  Active liver disease Indicated by AST/ALT higher than 3 times the upper limit of&#xD;
             normal&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  On drugs with interactions (Cyclosporine, gemfibrozil, lopinavir/ritonavir or&#xD;
             atazanavir/ritonavir, niacin) Severe renal impairment not on dialysis&#xD;
&#xD;
          -  Creatinine clearance &lt; 30 ml/min/1.73 m2&#xD;
&#xD;
          -  Known myopathy and inflammatory diasthesis (such as systemic lupus erythromatosus,&#xD;
             rheumatoid arthritis, and inflammatory bowel disease)&#xD;
&#xD;
          -  Human Immunodeficiency Virus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Genest, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RI-MUHC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 26, 2011</study_first_submitted>
  <study_first_submitted_qc>August 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2011</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Jacques Genest</investigator_full_name>
    <investigator_title>Co-Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

